Prajwal Boddu,Gautam Borthakur
Prajwal Boddu
Potential beneficial effects of sacubitril-valsartan in renal disease: a new field for a new drug [0.03%]
萨卡布曲缬沙坦在肾病中的潜在益处：新药的新领域
Guillermo Gervasini,Nicolas Roberto Robles
Guillermo Gervasini
Patients with renal dysfunction are at a higher risk of cardiovascular disease (CVD), which often shares manifestations with heart failure (HF). Last year, the FDA approved the use of sacubitril-valsartan in patients with HF. This dual-acti...
James N Gerson,Sam Skariah,Crystal S Denlinger et al.
James N Gerson et al.
The blockade of HER2 signaling has significantly improved the outlook for esophagogastric cancer patients. However, targeting HER2 still remains challenging due to complex biology of this receptor in gastric and esophageal cancers. Areas co...
Gerald H Tomkin,Daphne Owens
Gerald H Tomkin
Cardiovascular morbidity and mortality are of increasing concern, not only to patients but also to the health care profession and service providers. The preventative benefit of treatment of dyslipidaemia is unquestioned but there is a large...
Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease [0.03%]
临床前至II期淀粉样蛋白β（Aβ）肽调节剂的阿尔茨海默病研究
Chris G Parsons,Gerhard Rammes
Chris G Parsons
Alzheimer disease (AD) is the most common form of dementia and its incidence is increasing at an alarming rate all over the world. The pathophysiology of AD is characterized by chronic, progressive neurodegeneration which involves early syn...
Kirsten C Morley,Jennifer L Cornish,Alon Faingold et al.
Kirsten C Morley et al.
Methamphetamine use is a serious public health concern in many countries and is second to cannabis as the most widely abused illicit drug in the world. Effective management for methamphetamine dependence remains elusive and the large majori...
PPAR-α agonists are still on the rise: an update on clinical and experimental findings [0.03%]
PPAR-α激动剂后浪推前浪：临床和实验研究新进展
Nicola Ferri,Alberto Corsini,Cesare Sirtori et al.
Nicola Ferri et al.
Non-fasting plasma triglyceride (TG) and remnant cholesterol levels, cholesterol content of triglyceride-rich lipoproteins, have been suggested to be an additional cause of cardiovascular diseases; thus, pharmacological TG-lowering with fib...
A randomized, double-blind, single-dose, two-arm, parallel study comparing pharmacokinetics, immunogenicity and tolerability of branded adalimumab and its biosimilar LBAL in healthy male volunteers [0.03%]
一项在健康男性受试者中比较阿达木单抗原研药与LBAL相似药的药代动力学、免疫原性和耐受性的随机双盲平行对照单次给药研究
Kyoung Ryun Park,Hyewon Chung,Sung Mo Yang et al.
Kyoung Ryun Park et al.
Objectives: This study aimed to compare the pharmacokinetics (PK), immunogenicity, and tolerability of LBAL, a biosimilar of adalimumab, with the originator, Humira®, in healthy volunteers. ...
Randomized Controlled Trial
Expert opinion on investigational drugs. 2017 May;26(5):619-624. DOI:10.1080/13543784.2017.1307339 2017
Bradley T Endres,Eugénie Bassères,M Jahangir Alam et al.
Bradley T Endres et al.
Antibiotic development goals for CDI include potent antimicrobial effect against C. difficile, limited killing of host microbiota, potential effect on spores, and ability to interfere with toxin production. Cadazolid, a novel, non-absorbabl...